Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Biopharma enterprises have poured substantial resources into teaching employees how to write AI prompts, but prompt engineering is a rapidly depreciating skill as automated model capabilities render techniques obsolete. Conversely, validating AI outputs is a permanent, non-depreciating requirement that becomes harder as models become more fluent. The industry maintains an inverted capability balance by prioritizing prompt generation over rigorous output evaluation.

Related Insights

The explosion of AI-generated molecular candidates creates a new problem: physically testing them at scale. A significant portion of R&D effort should be redirected from AI model development to inventing novel, high-throughput instrumentation and assays to experimentally validate the flood of predictions AI produces.

As AI models advance and establish cleaner track records, human verification drops due to automation bias. A system that fails half as often, reviewed half as carefully, leaves biopharma companies in a worse position because remaining failures are subtler and masked by fluent prose. The apparent success of an AI pilot naturally lowers reviewer vigilance, allowing high-risk errors to circulate undetected.

As AI becomes more integrated into pharma, a need for validation will emerge. AI models used for medical affairs or commercial tasks will likely require accreditation from a neutral third party, similar to a 'certified pre-owned' car, to ensure reliability, compliance, and effectiveness.

Company-wide learning platforms are insufficient for pharma because they teach general AI principles. They fail to address the specific, high-stakes judgments required in functional workflows, like deciding if a generated regulatory summary is defensible or a promotional claim is substantiated, leaving employees with unanswered questions for their roles.

The true skill in using AI is no longer the prompt itself. The value lies "upstream" in identifying what work to delegate to AI and "downstream" in critically evaluating the output's accuracy and usefulness to advance a project.

Human verification catches AI output errors, but a deeper trust crisis is emerging. Executives, regulators, and partners are losing confidence in the underlying AI systems, their governance, and strategic recommendations, even when individual outputs are correct.

Research shows cognitive, accuracy-based skills (like judging if an AI-generated draft is defensible) erode far more quickly than procedural skills (like running a workflow). This means teams lose their most critical risk-management capability—the ability to spot a plausible but incorrect AI output—first.

As AI models become more intelligent, their ability to interpret ambiguous prompts in numerous ways increases. This makes precise, well-designed prompts more critical, not less, for achieving desired outcomes, thus increasing the value of prompt engineering skills.

The industry's critical need is for engineers who can build the entire support system for an LLM: contracts, validation, observability, cost controls, and failure handling. This "AI systems" skill set is more valuable than simply being able to craft a clever prompt for a single input.

AI skills decay over time, but cognitive, accuracy-dependent skills (like judging a regulator-facing output) erode three times faster than procedural skills (running a workflow). Companies often measure the slower-decaying half, missing the critical loss of judgment capability, which carries the most regulatory consequence.